Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.

The oncologist - 1 Feb 2021

Shah Kaustav P, Song Haocan, Ye Fei, Johnson Douglas B

Abstract excerpt

Agents blocking BRAF and MEK produce robust responses in patients with BRAFV600 -mutated melanoma; however, more accurate clinical biomarkers are needed to predict prognosis. To explore this question, we retrospectively studied 158 patients with BRAF-mutated melanoma treated with BRAF with or without MEK inhibitors. We found that the number of distinct tumor sites upon initiation of targeted therapy was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Melanoma
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33044751
DOI: 10.1002/onco.13562
PMCID: PMC7873326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.PMID 33044751Read ↗

Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.Semantic proximity Read ↗

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i> -Mutant MelanomaSemantic proximity Read ↗

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.Semantic proximity Read ↗

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.Semantic proximity Read ↗

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.Semantic proximity Read ↗

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.Semantic proximity Read ↗

Prognostic Significance of mEASIX, Inflammatory–Nutritional Biomarkers, Metastatic Patterns, and Treatment Characteristics in Metastatic Melanoma: A Multicenter Real-World Cohort StudySemantic proximity Read ↗

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.Semantic proximity Read ↗

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.Semantic proximity Read ↗

Prognostic value of BRAF mutations in localized cutaneous melanoma.Semantic proximity Read ↗

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.Semantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.